1
|
Rancati T, Badenchini F, La Rocca E, Pisani F, Gioscio E, Possenti L, Avuzzi B, Chiorda BN, Giandini C, Colciago RR, De Santis MC, Iacovelli NA, Franceschini M, Giandini T, Cavallo A, Cicchetti A. The Microvascular Health Status Predicts Radio-Induced Acute Toxicities in Breast, Prostate and Head and Neck Cancer Patients. Int J Radiat Oncol Biol Phys 2023; 117:S32-S33. [PMID: 37784477 DOI: 10.1016/j.ijrobp.2023.06.297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) investigate the role of healthy/unhealthy microcirculation in predicting acute toxicity (tox) after breast (BC), prostate (PC) and Head & Neck (HNC) cancer RT. MATERIALS/METHODS We enrolled BC patients (pts) treated with hypofractionated-RT after conservative surgery (42.4 Gy + 10 Gy boost to tumor bed), PC pts receiving radical-RT (65 Gy / 25 fractions), HNC pts treated with conventional RT (54-70 Gy @ 1.8-2 Gy/fr) or moderately hypofractionation (56.1-69.96 Gy @ 1.7-2.12 Gy/fr). We assessed baseline sublingual-microvasculature (MV) health status before RT using a sidestream dark-field camera coupled to the GlycoCheck™ software. The system records videos showing the live movement of red blood cells (RBCs) in the microvessels. It computes 5 functional parameters: (a) perfused boundary region (PBR) estimating the penetration of RBCs into the permeable part of the endothelial glycocalyx (higher PBR values result from damaged glycocalyx, indicating impaired microcirculation); (b) density of capillaries (1/mm2); (c) blood flow in the recorded area (103 μm3/s/mm2); (d) recruitment capacity (quantifying the ability to recruit additional capillaries); (e) a global MV_HealthScore (MVHS), higher values indicate healthier MV. MVHS is computed by weighting information from the previous parameters. The computation of MVHS needs a prolonged video acquisition not reached by less compliant patients. Endpoint for this analysis was acute tox. We selected a clinically relevant tox endpoint for each cancer site: grade≥2 erythema (G2+E) for BC, any grade≥3 tox (G3Tox) for HNC and persistent grade≥1 tox simultaneously present in gastrointestinal and genitourinary domains (G1+GIGU) for PC. We used logistic regression to assess MV functional parameters' association with toxicity. RESULTS We evaluated 63 BC, 38 PC, 39 HNC pts. 77 (55%) had an evaluation for MVHS. 23/63 BC pts presented with G2+E, 12/38 PC pts with G1+GIGU, 12/39 HNC pts with G3Tox. Average MVHS was 3.6, 3.2, 2.7 in BC, HNC and PC, respectively (P>0.15). The MVHS associated with tox: healthy MV protects from tox (continuous, OR = 0.66 for 1 point increase, p = 0.01, AUC 0.69). Categorizing pts as low MVHS (<2.5), average MVHS (2.5-6.5) and high MVHA (>6.5), the observed toxicity rates in the 3 classes were 50%, 26%, 0% (p = 0.02). Also, a 3-variate model including the separated functional parameters predicted tox (AUC 0.67) on the 144 pts: higher PBR is a risk (OR = 7.6), higher capillary density protects (Logarithm, OR 0.002), higher blood flow is a risk (Logarithm, OR = 14.2). CONCLUSION These data suggest an interaction of compromised MV with repair mechanisms. The MVHS model predicts acute toxicity in BC/PC/HN pts proving (i) a quantitative relationship between MV state and radio-susceptibility and (ii) in an organ-agnostic way. The systemic functional information derived by the sublingual microscope could boost the personalization of predictive models and tailor them to the single-patient functional status. Funded by AIRC IG 21479.
Collapse
Affiliation(s)
- T Rancati
- Fondazione IRCCS Istituto Nazionale dei Tumori, Data Science Unit, Milan, Italy
| | - F Badenchini
- Fondazione IRCCS Istituto Nazionale dei Tumori, Unit of GenitoUrinary Oncology, Milan, Italy
| | - E La Rocca
- Department of Radiation Oncology, University of Verona Hospital Trust, Verona, Italy
| | - F Pisani
- Fondazione IRCCS Istituto Nazionale dei Tumori, Data Science Unit, Milan, Italy
| | - E Gioscio
- Fondazione IRCCS Istituto Nazionale dei Tumori, Data Science Unit, Milan, Italy
| | - L Possenti
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - B Avuzzi
- Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Radiation Oncology, Milan, Italy
| | - B Noris Chiorda
- Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Radiation Oncology, Milan, Italy
| | - C Giandini
- Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Radiation Oncology, Milan, Italy
| | - R R Colciago
- Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Radiation Oncology, Milan, Italy
| | - M C De Santis
- Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Radiation Oncology, Milan, Italy
| | - N A Iacovelli
- Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Radiation Oncology, Milan, Italy
| | - M Franceschini
- Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Radiation Oncology, Milan, Italy
| | - T Giandini
- Fondazione IRCCS Istituto Nazionale dei Tumori, Division of Medical Physics, Milan, Italy
| | - A Cavallo
- Fondazione IRCCS Istituto Nazionale dei Tumori, Division of Medical Physics, Milan, Italy
| | - A Cicchetti
- Fondazione IRCCS Istituto Nazionale dei Tumori, Data Science Unit, Milan, Italy
| |
Collapse
|
2
|
Casbarra A, Frassoni S, Fodor C, Ferrari A, Cambria R, Colombo F, Franzetti J, Giandini C, Repetti I, Bagnardi V, Della Pasqua S, Colleoni M, Leonardi M, Jereczek-Fossa B. PO-1181 The impact of RT on oligorecurrent BC: a retrospective analysis of predictors of clinical outcome. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03145-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
3
|
La Rocca E, Lozza L, D' Ippolito E, Dispinzieri M, Giandini C, Bonfantini F, Valdagni R, Folli S, Pignoli E, Di Cosimo S, De Santis MC. VMAT partial-breast irradiation: acute toxicity of hypofractionated schedules of 30 Gy in five daily fractions. Clin Transl Oncol 2020; 22:1802-1808. [PMID: 32128672 DOI: 10.1007/s12094-020-02319-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2019] [Accepted: 02/08/2020] [Indexed: 12/01/2022]
Abstract
PURPOSE To report acute toxicities in breast cancer (BC) patients (pts) recruited in a prospective trial and treated with accelerated partial-breast irradiation (APBI) using Volumetric Modulated Arc Therapy (VMAT) delivered with a hypofractionated schedule. METHODS From March 2014 to June 2019, pts with early-stage BC (Stage I), who underwent breast conservative surgery (BCS), were recruited in a prospective study started at the National Cancer Institute of Milan. Pts received APBI with a hypofractionated schedule of 30 Gy in five daily fractions. Radiotherapy treatment (RT) was delivered using VMAT. Acute toxicity was assessed according to RTOG/EORTC criteria at the end of RT. RESULTS Between March 2014 and June 2019, 151 pts were enrolled in this study. 79 Pts had right-side and 72 had left-side breast cancer. Median age was 69 (range 43-92). All pts presented with pathological stage IA BC, molecular classification was Luminal A in 128/151 (85%) and Luminal B in 23/151 (15%) cases. Acute toxicity, assessed at the end of RT, consisted of G1 erythema in 37/151 (24. 5%) pts and skin toxicities higher than G1, did not occur. Fibrosis G1 and G2 were reported in 41/151 (27. 1%) pts and in 2/151 pts (1. 3%), respectively. Edema G1 occurred in 8/151 (5. 3%) pts and asthenia G1 occurred in 1/151 (0. 6%) pts. CONCLUSIONS APBI with VMAT proved to be feasible and can be a valid alternative treatment option after BCS in selected early breast cancer pts according to ASTRO guidelines. A longer follow-up is needed to assess late toxicity.
Collapse
Affiliation(s)
- E La Rocca
- Radiotherapy Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.,Department of Oncology and Hemato-Oncology, Università Degli Studi Di Milan, Milano, Italy
| | - L Lozza
- Radiotherapy Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - E D' Ippolito
- Medical Physics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - M Dispinzieri
- Radiotherapy Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - C Giandini
- Radiotherapy Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.,Department of Oncology and Hemato-Oncology, Università Degli Studi Di Milan, Milano, Italy
| | - F Bonfantini
- Medical Physics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.,Radiotherapy and Oncology Unit, ASST Bergamo Ovest, Treviglio, Italy
| | - R Valdagni
- Department of Oncology and Hemato-Oncology, Università Degli Studi Di Milan, Milano, Italy.,Radiation Oncology 1 and Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - S Folli
- Breast Surgery Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - E Pignoli
- Medical Physics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - S Di Cosimo
- Biomarker Unit, Department of Applied Research and Technological Development (DRAST), Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - M C De Santis
- Radiotherapy Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
| |
Collapse
|